Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Olema Pharmaceuticals ( (OLMA) ) has provided an update.
Olema Pharmaceuticals has announced FDA clearance for its Investigational New Drug application for OP-3136, a promising small molecule targeting KAT6, implicated in breast cancer. The company is set to start Phase 1 clinical trials in early 2025. Additionally, Olema shared positive interim results from a Phase 1b/2 study combining palazestrant with ribociclib, showing encouraging tumor response and safety in treating advanced breast cancer, positioning palazestrant for further development.
For an in-depth examination of OLMA stock, go to TipRanks’ Stock Analysis page.
